Biophytis Sa · EURONEXT:ALBPS
Biophytis Sa — Shareholder Meeting (May 2021)
27 slides from Biophytis Sa's shareholder meeting presentation, May 10, 2021
Slide 1: AGM May 10, 2021
AGM May 10, 2021 May 2021 I Euronext: ALBPS – Nasdaq: BPTS
Slide 2: Forward Looking Statements
Forward Looking Statements All statements pertaining to future financial and/or operating results, future growth in research, clinical development, and potential opportunities for Biophytis SA (the “Company”) and its products, along with other statements about the future expectations, beliefs, goals
Slide 3: Agenda
Agenda Quorum 2021 AGM Second 1 call 2 Pipeline & key milestones 3 2020 Key financial highlights 2021 AGM resolutions & 4 vote results 29
Slide 4: AGM May 2021 – Second call quorum
AGM May 10 2021 – Second call quorum • Biophytis’ second call combined AGM took place today behind closed doors, due to the COVID-19 pandemic. • The shareholders taking part in the vote owned collectively 24 994 687 shares, or 22,37% of the share capital, and 22.82% of the voting rights. 30
Slide 5: Our clinical pipeline is progressing and expanding since last year
Our clinical pipeline is progressing and expanding since last year Candidate Indication Program Preclinical Phase 1 Phase 2 Phase 3 Covid-19 COVA Sarconeos Sarcopenia SARA (BIO101) DMD MYODA Dry AMD MACA Macuneos (BIO201) Stargardt • Second generation drug candidates, BIO103 and BIO203, are life-cyc
Slide 6: Key programs milestones
Key programs milestones COVA Started in Belgium, Brazil, France and US COVA Completion of patient enrollment (Part 1) in January 2021 COVA Interim analysis of Part 1 (50 patients) in Q1 2021 COVA Approvals to start Part 2 in Q1 2021 COVA Interim analysis for Part 2 (155 patients) expected before end
Slide 7: Successful US IPO in addition to PIPEs on Euronext totaling €40M
Successful US IPO in addition to PIPEs on Euronext totaling €40M U.S. Initial Public Offering 2020 Euronext Financings In February 2021, the Company closed an The Company successfully closed four private initial public offering on the NASDAQ placement transactions (BPTS) Public offering gross procee
Slide 8: Stabilized loss in 2020 despite the start of COVA, thanks to lower G&A spendings
Stabilized loss in 2020 despite the start of COVA, thanks to lower G&A spendings Consolidated Operating Results (M€) 2019 2020 Net Research and Development expenses 9.1 9.9 General and administrative expenses 6.6 4.0 Operating loss (15.7) (13.9) Net financial loss (2.1) (3.1) Loss before tax (17.8)
Slide 9: Cash and current financial assets improved from 6.8M€ to 18.8M€
Cash and current financial assets improved from 6.8M€ to 18.8M€ Consolidated Assets (M€) 2019 2020 Patents and software 2.4 2.7 Property, plant and equipment 0.2 0.1 Other non-current financial assets 0.4 0.4 Total non-current assets 3.0 3.2 Other receivables 7.9 5.3 Other current financial assets 0
Slide 10: Cash flows: higher resources mainly due to successful financing activities
Cash flows: higher resources mainly due to successful financing activities Consolidated Net cash (use)/sources (M€) 2019 2020 Operating activities (15.3) (9.9) Investing Activities (inc. 12.5M€ in term deposit in (0.3) (12.7) 2020) Financing Activities 7.5 22.1 Net increase (decrease) in cash and ca
Slide 11: Net equity significantly strengthened, and financial debts decreased
Net equity significantly strengthened, and financial debts decreased Consolidated Liabilities (M€) 2019 2020 Share capital 4.8 20.2 Premiums related to the share capital 45.2 17.8 Accumulated deficit (39.7) (14.1) Net loss (17.8) (17.1) Total shareholders' equity (7.5) 6.8 Employee benefit obligatio
Slide 12: Ordinary Resolutions
Ordinary Resolutions #1: Approval of the financial accounts for the financial year ended on December 31st, 2020, #2: Approval of the consolidated financial accounts for the financial year ended on December 31st, 2020, #3: Allocation and distribution of net income for the financial year ended on Dece
Slide 13: Extraordinary Resolutions- Delegation to issue new shares and debt
Extraordinary Resolutions- Delegation to issue new shares and debt #10: Delegation of authority to the Board of Directors under the provisions of Article L. 225-129-2 of the French commercial Code to decide to issue shares and/or securities giving immediate or future access to the share capital or g
Slide 14: Extraordinary Resolutions — Other Delegations
Extraordinary Resolutions — Other Delegations #16: Authorization to be granted to the Board of Directors to increase the number of shares and/or securities giving immediate or future access to the share capital or giving the right to a debt security in accordance with the provisions of article L. 22
Slide 15: AGO votes results
AGO votes results Resolution N°1 (AGO) Number of Voting rights Number of Shares Shares (%) Voting 25 656 224 24 994 687 21,96% Exclusions 0 0 0,00% Number of Voting rights Percentage For 24 806 012 97,582% Against 614 757 2,418% Resolution Abstain 235 455 0,918% Adopted Void 0 0,000% Blank 0 0,000%
Slide 16: AGO votes results
AGO votes results Resolution N°4 (AGO) Number of Voting rights Number of Shares Shares (%) Voting 21 937 682 24 994 687 21,96% Exclusions 3 718 542 0 0,00% Number of Voting rights Percentage For 21 007 791 96,989% Against 652 105 3,011% Resolution Abstain 277 786 1,266% Adopted Void 0 0,000% Blank 0
Slide 17: AGO votes results
AGO votes results Resolution N°7 (AGO) Number of Voting rights Number of Shares Shares (%) Voting 25 656 224 24 994 687 21,96% Exclusions 0 0 0,00% Number of Voting rights Percentage For 23 619 585 93,359% Against 1 680 243 6,641% Resolution Abstain 356 396 1,389% Adopted Void 0 0,000% Blank 0 0,000
Slide 18: AGO votes results
AGO votes results Resolution N°19 (AGO) Number of Voting rights Number of Shares Shares (%) Voting 25 656 224 24 994 687 21,96% Exclusions 0 0 0,00% Number of Voting rights Percentage For 23 667 437 93,093% Against 1 755 875 6,907% Resolution Abstain 232 912 0,908% Adopted Void 0 0,000% Blank 0 0,00
Slide 19: AGO votes results
AGO votes results Resolution N°19 (AGO) Number of Voting rights Number of Shares Shares (%) Voting 25 656 224 24 994 687 21,96% Exclusions 0 0 0,00% Number of Voting rights Percentage For 23 667 437 93,093% Against 1 755 875 6,907% Resolution Abstain 232 912 0,908% Adopted Void 0 0,000% Blank 0 0,00
Slide 20: AGO votes results
AGO votes results Resolution N°28 (AGO) Number of Voting rights Number of Shares Shares (%) Voting 25 656 224 24 994 687 21,96% Exclusions 0 0 0,00% Number of Voting rights Percentage For 24 350 574 95,935% Against 1 031 870 4,065% Resolution Abstain 273 780 1,067% Adopted Void 0 0,000% Blank 0 0,00
Slide 21: AGO votes results
AGO votes results Resolution N°31 (AGO) Number of Voting rights Number of Shares Shares (%) Voting 25 656 224 24 994 687 21,96% Exclusions 0 0 0,00% Number of Voting rights Percentage For 24 580 676 97,053% Against 746 409 2,947% Resolution Abstain 329 139 1,283% Adopted Void 0 0,000% Blank 0 0,000%
Slide 22: AGE votes results
AGE votes results Resolution N°10 (AGE) Number of Voting rights Number of Shares Shares (%) Voting 25 656 224 24 994 687 21,96% Exclusions 0 0 0,00% Number of Voting rights Percentage For 22 269 001 87,712% Against 3 119 859 12,288% Resolution Abstain 267 364 1,042% Adopted Void 0 0,000% Blank 0 0,0
Slide 23: AGE votes results
AGE votes results Resolution N°13 (AGE) Number of Voting rights Number of Shares Shares (%) Voting 25 656 224 24 994 687 21,96% Exclusions 0 0 0,00% Number of Voting rights Percentage For 22 381 263 88,048% Against 3 038 135 11,952% Resolution Abstain 236 826 0,923% Adopted Void 0 0,000% Blank 0 0,0
Slide 24: AGE votes results
AGE votes results Resolution N°16 (AGE) Number of Voting rights Number of Shares Shares (%) Voting 25 656 224 24 994 687 21,96% Exclusions 0 0 0,00% Number of Voting rights Percentage For 22 642 315 89,650% Against 2 614 019 10,350% Resolution Abstain 399 890 1,559% Adopted Void 0 0,000% Blank 0 0,0
Slide 25: AGE votes results
AGE votes results Resolution N°20 (AGE) Number of Voting rights Number of Shares Shares (%) Voting 25 656 224 24 994 687 21,96% Exclusions 0 0 0,00% Number of Voting rights Percentage For 24 633 551 96,868% Against 796 555 3,132% Resolution Abstain 226 118 0,881% Adopted Void 0 0,000% Blank 0 0,000%
Slide 26: AGE votes results
AGE votes results Resolution N°23 (AGE) Number of Voting rights Number of Shares Shares (%) Voting 25 656 224 24 994 687 21,96% Exclusions 0 0 0,00% Number of Voting rights Percentage For 22 417 211 88,899% Against 2 799 398 11,101% Resolution Abstain 439 615 1,713% Adopted Void 0 0,000% Blank 0 0,0
Slide 27: Thank you
CONTACTS: Stanislas Veillet – CEO stanislas.veillet@biophytis.com Evelyne NGUYEN – CFO evelyne.nguyen@biophytis.com Thank you Investor relations: investors@biophytis.com Website: www.biophytis.com 53